2 results
Approved WMOCompleted
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
Approved WMOCompleted
Objective: To evaluate the anatomical success of MOCA versus RFA in treatment of symptomatic insufficient SSV.